BOEHRINGER-INGELHEIM
Boehringer Ingelheim today announced that it will present important new data on the treatment of patients with atrial fibrillation (AF) at the ESC Congress in Barcelona, Spain, 26-30 August 2017. In total, four abstracts have been accepted, investigating different aspects of AF patient treatment. The results of the RE-DUAL PCI™ trial have been selected for one of the Late Breaking Science sessions of the congress.
The RE-DUAL PCI™ trial compared dual therapy with triple therapy after percutaneous coronary intervention (PCI) with stent placement in approximately 2,500 adults with atrial fibrillation. Patients were either treated with dabigatran etexilate (Pradaxa® ) and a single antiplatelet agent or with the vitamin K antagonist (VKA) warfarin and two antiplatelets. The dabigatran doses investigated in this trial are the same doses which have already demonstrated effective stroke prevention in atrial fibrillation and are therefore approved around the world in this indication.1
“The presentation of the results of our RE-DUAL PCI™ trial at ESC is particularly timely as the focus of the 2017 congress is ‘40 years of PCI’”, commented Professor Jörg Kreuzer, Vice President Medicine, Therapeutic Area Cardiovascular, Boehringer Ingelheim. “We are honoured that the results will be included in the congress Spotlight Session and hope that the findings from the trial will provide a valuable contribution to patient management in the PCI setting.”
Details of the data presented at the ESC 2017 are as follows:
Abstract Title |
Details
(Venue: Fira Gran Via, Barcelona) |
||
RE-DUAL PCI™: Dual antithrombotic therapy with dabigatran after percutaneous coronary intervention in patients with atrial fibrillation1 | ‘Late-breaking Science in PCI 2’ Spotlight of the Congress (1920), 14:45-15:00, 27 August, Spotlight Stage, Speaker Christopher Cannon | ||
Medication burden and perception of anticoagulation treatments in atrial fibrillation patients: results from an international survey2 | ‘Poster session 4: Stroke prevention’ (P3618), 08:30-12:30, 28 August, Poster Area, Speaker Deidre Lane | ||
Prescribing of dabigatran etexilate in accordance with the European label for stroke prevention in atrial fibrillation: Findings from the GLORIA-AF™ Registry3 | ‘Poster session 5: Registries and cost of treatment’ (P4600) 14:00-18:00, 28 August, Poster Area, Speaker Gregory Lip | ||
Development and validation of a novel biomarker-based risk score to improve the prediction of death in patients with atrial fibrillation4 | ‘Stroke risk prediction in atrial fibrillation’ session (5770), 14:54-15:12, 29 August, Valetta – Village 5, Speaker Ziad Hijazi |
More information on the Boehringer Ingelheim data due to be presented or published at the ESC Congress can be found here.
~ENDS~
Please click on the link below for ‘Notes to Editors and References’:
http://www.boehringer-ingelheim.com/press-release/esc-2017
View source version on businesswire.com: http://www.businesswire.com/news/home/20170821005286/en/
Contact:
Boehringer Ingelheim GmbH
Friederike Middeke
Phone:
+49 6132 – 77 141575
Fax:
+49 6132 – 77 6601
E-mail:
press@boehringer-ingelheim.com
Twitter:
http://twitter.com/Boehringer
or
More
information
www.boehringer-ingelheim.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LIBERTEX29.3.2024 06:26:33 CET | Press release
PAN Finance Names Libertex ‘Global CFD Broker of the Year’
MIDEA-GROUP29.3.2024 02:40:30 CET | Press release
Midea Group releases its first-ever ESG brand story with an unexpected VIP visit highlighting its commitment to sustainability.
NY-DC-ADMINISTRATION28.3.2024 21:15:26 CET | Press release
DC Secretary Announces Annual Determinations Committees Outcome
CA-HTEC/G2-RISK28.3.2024 17:03:32 CET | Press release
Faster Recoveries, Improved Security: HTEC and G2 Risk Solutions Join Forces to Advance Bankruptcy Management
YCVB28.3.2024 16:01:31 CET | Press release
The reopening of the Yokohama Museum of Art adds another innovative and distinctive venue for events in Yokohama
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom